Annotation Detail
Information
- Associated Genes
- BRCA2
- Associated Variants
-
BRCA2 LOSS-OF-FUNCTION
BRCA2 LOSS-OF-FUNCTION - Associated Disease
- pancreatic cancer
- Source Database
- CIViC Evidence
- Description
- Veliparib 400mg bid was administered to patients with germline BRCA1/2 mutated pancreatic cancer. Sixteen pts was enrolled. All except two pts (12.5%) had previously been treated with platinum therapy. No confirmed PR was observed. One patient who had received prior single-agent gemcitabine only had an unconfirmed PR.
- Variant Origin
- germline
- Variant Origin
- Rare Germline
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/5935
- Gene URL
- https://civic.genome.wustl.edu/links/genes/7
- Variant URL
- https://civic.genome.wustl.edu/links/variants/186
- Rating
- 3
- Evidence Type
- Predictive
- Disease
- Pancreatic Cancer
- Evidence Direction
- Does Not Support
- Drug
- Veliparib
- Evidence Level
- B
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 29223478
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Veliparib | Sensitivity | false |